AstraZeneca PLC (AZN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com11-13

Total Revenue Growth (Q3 2024): 21% increase. Core EPS Growth (Q3 2024): 27% increase to $2.8. Year-to-Date Total Revenue Growth (2024): 19% increase. Year-to-Date Core EPS Growth (2024): 11% increase...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483023300?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XhiUaFAIA4ClmjrzGQoQHg--~B/aD0zNTc7dz0zMjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/0a6705b2a61eb869e31c2112a981b4b3","is_english":true,"pubTime":"2024-11-13 15:12","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483023300","market":"us","top_or_hot":-1,"title":"AstraZeneca PLC (AZN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...","media":"GuruFocus.com","content":"<div>\n<p>Total Revenue Growth (Q3 2024): 21% increase.\nCore EPS Growth (Q3 2024): 27% increase to $2.8.\nYear-to-Date Total Revenue Growth (2024): 19% increase.\nYear-to-Date Core EPS Growth (2024): 11% increase...</p>\n\n<a href=\"https://finance.yahoo.com/news/astrazeneca-plc-azn-q3-2024-071253839.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca PLC (AZN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca PLC (AZN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 15:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/astrazeneca-plc-azn-q3-2024-071253839.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Total Revenue Growth (Q3 2024): 21% increase.\nCore EPS Growth (Q3 2024): 27% increase to $2.8.\nYear-to-Date Total Revenue Growth (2024): 19% increase.\nYear-to-Date Core EPS Growth (2024): 11% increase...</p>\n\n<a href=\"https://finance.yahoo.com/news/astrazeneca-plc-azn-q3-2024-071253839.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"https://finance.yahoo.com/news/astrazeneca-plc-azn-q3-2024-071253839.html","article_id":"2483023300","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XhiUaFAIA4ClmjrzGQoQHg--~B/aD0zNTc7dz0zMjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/0a6705b2a61eb869e31c2112a981b4b3"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483023300","pubTimestamp":1731481973,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Core EPS Growth : 27% increase to $2.8.Emerging Markets Growth : 30% increase outside of China.Oncology Total Revenue : $16 billion, 22% growth.BioPharmaceuticals Total Revenue : $15.9 billion, 20% growth.Rare Disease Revenue : $6.4 billion, 14% growth.Net Cash Inflow from Operating Activities : Improved by $989 million.Full Year Guidance Upgrade : Total revenue and core EPS expected to grow by high 10s percentage.GuruFocus has detected 5 Warning Sign with AZN.For the complete transcript of the earnings call, please refer to the full earnings call transcript.AstraZeneca PLC  reported a 21% increase in total revenue for Q3, driven by strong global demand for its medicines.Core EPS increased by 27% to $2.8, reflecting a continued focus on profitability.AstraZeneca PLC  faces potential headwinds from the Inflation Reduction Act  and VBP in China, which could impact future growth.Operating expenses increased by 15% year-to-date, with R&D expenses rising by 18% due to recent acquisitions an","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"AstraZeneca PLC(AZN)2024年第三季度收益看涨期权亮点：强劲的收入增长和战略……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"Total Revenue Growth (Q3 2024): 21% increase.\nCore EPS Growth (Q3 2024): 27% increase to $2.8.\nYear-to-Date Total Revenue Growth (2024): 19% increase.\nYear-to-Date Core EPS Growth (2024): 11% increase.\nEmerging Markets Growth (Year-to-Date 2024): 30% increase outside of China.\nOncology Total Revenue (First Nine Months 2024): $16 billion, 22% growth.\nBioPharmaceuticals Total Revenue (First Nine Months 2024): $15.9 billion, 20% growth.\nRare Disease Revenue (First Nine Months 2024): $6.4 billion, 14% growth.\nNet Cash Inflow from Operating Activities (First Nine Months 2024): Improved by $989 million.\nCapEx (Year-to-Date 2024): $1.2 billion.\nNet Debt Increase (First Nine Months 2024): $3.8 billion.\nNet Debt to EBITDA Ratio: 1.8 times.\nFull Year Guidance Upgrade (2024): Total revenue and core EPS expected to grow by high 10s percentage.\n\n\nWarning! GuruFocus has detected 5 Warning Sign with AZN.\n\nRelease Date: November 12, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nAstraZeneca PLC (NASDAQ:AZN) reported a 21% increase in total revenue for Q3, driven by strong global demand for its medicines.\nCore EPS increased by 27% to $2.8, reflecting a continued focus on profitability.\nThe company upgraded its full-year guidance, expecting total revenue and core EPS to increase by high teens percentages.\nAstraZeneca PLC (NASDAQ:AZN) announced a $3.5 billion investment in the US for manufacturing and R&D, highlighting its commitment to the US market.\nThe company delivered multiple high-value phase readouts, with several medicines showing potential for significant revenue contributions.\n\n Negative Points \n\nAstraZeneca PLC (NASDAQ:AZN) faces potential headwinds from the Inflation Reduction Act (IRA) and VBP in China, which could impact future growth.\nThe company is dealing with ongoing investigations in China, which could have an uncertain impact on its operations and revenue.\nOperating expenses increased by 15% year-to-date, with R&D expenses rising by 18% due to recent acquisitions and accelerated projects.\nThe company anticipates a lower product sales gross margin in the fourth quarter, partly due to seasonality and increased supply costs.\nNet debt increased by $3.8 billion, reflecting acquisitions and dividend payments, with a net debt to EBITDA ratio of 1.8 times.\n\n Q & A Highlights \nQ: How might the upcoming US Presidential election impact AstraZeneca's business, and is there a strategic shift towards more US investment? A: Pascal Soriot, CEO, explained that pharmaceuticals are typically not subject to import duties, and AstraZeneca sources its products for the US from either the US or Europe. The US is a critical market for innovation and patient access, prompting a $3.5 billion investment in US manufacturing and R&D. The company aims to increase its US revenue share, driven by new product launches and market growth.\nQ: What is AstraZeneca's confidence level in achieving the 2025 growth outlook, considering potential headwinds like China and IRA? A: Pascal Soriot expressed confidence in the 2025 outlook, citing strong momentum with nearly 20% top-line growth. Despite known headwinds such as IRA and potential impacts in China, the company expects continued global demand and strategic leverage to support growth.\nQ: Can you comment on the potential impact of the ongoing investigations in China on AstraZeneca's business? A: Pascal Soriot stated it's too early to judge the impact, but it's reasonable to assume some effect. China represents about 12-13% of total revenue, and while growth may slow next year due to factors like VBP, the company remains committed to its presence and investment in China.\nQ: What is the status of the regulatory review for datopotamab deruxtecan (data DXD) in the US, and what are the expectations for approval timelines? A: Susan Galbraith, EVP of Oncology R&D, mentioned that the BLA for data DXD has been submitted, and the company has applied for breakthrough therapy designation. If granted, this could lead to a priority review, potentially expediting the approval process.\nQ: How is AstraZeneca addressing compliance issues in China, and are there similar concerns in other regions? A: Pascal Soriot highlighted that the compliance issues in China were specific to certain market conditions, such as reimbursement discrepancies. The company has strengthened its compliance systems globally, including field compliance officers and rotation of regional sales directors, to prevent similar issues elsewhere.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483023300"}